^
    4ms
    ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
    P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc. | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • XP-102
    over1year
    ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
    P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc. | Initiation date: Jun 2022 --> Dec 2022
    Trial initiation date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • XP-102
    2years
    ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
    P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc.
    New P1/2 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • XP-102